Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Iterum Therapeutics plc (ITRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 2,155 7,332 Other income, net 50 269 91 431 Income tax expense Net loss $ $ $ $ Net loss per share – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,942,969 12,224,324 12,812,398 12,208,961 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortization 429 429 858 858 Share based compensation 110 1,984 503 3,879 Interest expense - accrued interest and amortization on Exchang..."
08/01/2023 8-K Quarterly results
07/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/03/2023 4 Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 1,779 options to buy @ $0
07/03/2023 4 HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 2,796 options to buy @ $0
06/15/2023 4 Hecht Beth (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 15,853 options to buy @ $0
06/15/2023 4 Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 15,853 options to buy @ $0
06/15/2023 4 Chin Mark (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 15,853 options to buy @ $0
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest expense, net Adjustments to fair value of derivatives 5,177 Other income, net 41 162 Income tax expense Net loss $ $ Net loss per share – basic and diluted $ $ Weighted average ordinary shares outstanding – basic and diluted 12,681,900 12,193,435 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ Intangible asset amortization 429 429 Share based compensation 393 1,895 Interest expense - accrued interest and amortization on Exchangeable Notes 783 783 Adjustments to fair value of derivatives 878 Non-GAAP net loss $ $ Net loss per share ..."
05/04/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Iterum Therapeutics public limited company. 2. The Company is a public limited company for the purposes of Part 17 of the Companies Act 2014. 3. The objects for which the Company is established are: a. To carry on the business of a holding company and to coordinate the administration, finances and activities of any subsidiary companies or associated companies, to do all lawful acts and things whatsoever that are necessary or convenient in carrying on the business of such a holding company and in particular to carry on, in all..."
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/03/2023 4 HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 2,041 options to buy @ $0
04/03/2023 4 Matthews Judith M. (CFO) has filed a Form 4 on Iterum Therapeutics plc
Txns: Granted 100,000 options to buy @ $1, valued at $100k
04/03/2023 4 Puttagunta Sailaja (Chief Medical Officer) has filed a Form 4 on Iterum Therapeutics plc
Txns: Granted 75,000 options to buy @ $1, valued at $75k
04/03/2023 4 Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 1,299 options to buy @ $0
04/03/2023 4 Fishman Corey N. (CEO) has filed a Form 4 on Iterum Therapeutics plc
Txns: Granted 275,000 options to buy @ $1, valued at $275k
03/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/16/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "ITERUM THERAPEUTICS PLC Condensed Consolidated Statement of Operations For the three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development General and administrative Total operating expenses Operating loss Interest income / , net 80 Adjustments to fair value of derivatives 2,960 3,562 5,458 Cancellation of share options - - - Other income, net 28 503 195 Income tax expense Net loss attributable to ordinary shareholders $ $ $ $ Net loss per share attributable to ordinary shareholders – basic and diluted $ $ $ $ Weighted average ordinary shares outstanding – basic and diluted 12,294,865 12,185,019 12,236,607 10,891,178 Reconciliation of non-GAAP net loss to GAAP net loss Net loss - GAAP $ $ $ $ Intangible asset amortiza..."
03/14/2023 4 Matthews Judith M. (CFO) has filed a Form 4 on Iterum Therapeutics plc
Txns: Granted 6,666 shares @ $0
Paid exercise price by delivering 2,883 shares @ $0.96, valued at $2.8k
Exercised 6,666 options to buy @ $0
03/14/2023 4 Fishman Corey N. (CEO) has filed a Form 4 on Iterum Therapeutics plc
Txns: Granted 14,333 shares @ $0
Paid exercise price by delivering 5,683 shares @ $0.96, valued at $5.5k
Exercised 14,333 options to buy @ $0
03/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/27/2023 4/A Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc
01/04/2023 4 Dunne Michael W. (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 761 options to buy @ $0
01/04/2023 4 HUNT RONALD (Director) has filed a Form 4 on Iterum Therapeutics plc
Txns: Exercised 1,197 options to buy @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy